|Blackman A, Boutin A, Shimanovsky A, Baker WJ, Forcello N. "Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature." Journal of Oncology Pharmacy Practice, vol. 24, no. 5, 2018, pp. 393-397.|
|Shimanovsky A, Alvarez Argote J, Murali S, Dasanu CA. "Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance." BBA clinical, vol. 6, 2016, pp. 12-8.|
|Shimanovsky A, Patel D, Wasser J. "Refractory Immune Thrombocytopenic Purpura and Cytomegalovirus Infection: A Call for a Change in the Current Guidelines." Mediterranean journal of hematology and infectious diseases, vol. 8, no. 1, 2016, pp. e2016010.|
|Phuong L, Shimanovsky A. "Superior Sagittal Sinus Thrombosis Related to the Use of Tamoxifen: A Case Report and Review of Literature." Connecticut medicine, vol. 80, no. 8, 2016, pp. 487-489.|
|Shimanovsky A, Dasanu CA. "Updates on immunotherapy in non-small cell lung cancer." Expert opinion on biological therapy, vol. 14, no. 4, 2014, pp. 411-8.|
|Shimanovsky A, Bauer F, Silver J, Lamana S, Dasanu CA. "A case of polycythemia rubra vera transforming into chronic phase JAK2 V617F mutation-negative Philadelphia chromosome-positive chronic myelogenous leukemia." Leukemia & lymphoma, vol. 54, no. 7, 2013, pp. 1567-8.|
|Dasanu CA, Shimanovsky A, Rotundo EK, Posteraro AF, Cooper DL, Atienza JA. "Collision tumors: pancreatic adenocarcinoma and mantle cell lymphoma." JOP : Journal of the pancreas, vol. 14, no. 4, 2013, pp. 458-62.|
|Shimanovsky A, Jethava A, Dasanu CA. "Immune alterations in malignant melanoma and current immunotherapy concepts." Expert opinion on biological therapy, vol. 13, no. 10, 2013, pp. 1413-27.|
|Dasanu CA, Shimanovsky A, Jain K, Codreanu I. "Mediastinal choriocarcinoma presenting with syncope." Connecticut medicine, vol. 77, no. 8, 2013, pp. 473-5.|
|Shimanovsky A, Dasanu CA. "Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma." Expert opinion on pharmacotherapy, vol. 14, no. 4, 2013, pp. 515-23.|
1.Immunohistochemical staining for programmed cell-death ligand 1 (PD-L1) in malignant thymoma and thymic carcinoma.
2. Association between pioglitazone (PZD) therapy and bladder cancer (BC): A meta-analysis of epidemiologic evidence.
3. Emerging concepts in combination chemotherapy for metastatic pancreatic cancer: A systematic review of randomized controlled trials.